arnold's Discussions (62)

Search Discussions

View

Discussions Replied To (30) Replies Latest Activity

"Eteplirsen Phase IIB study met the primary endpoint of increase in novel dystrophin…"

arnold replied Apr 23, 2013 to Sarepta and their push for Accelerated Approval of Eteplirsen

 5 Apr 23, 2013
Reply by arnold

"you beat me   its still worth posting twice   thanks for catching it so quick and i…"

arnold replied Nov 15, 2011 to AVI Enters Into Collaborations for the Development of Two Additional Exon-Skipping Products for Duchenne Muscular Dystrophy (DMD)

 7 Feb 8, 2012
Reply by Traci Strafuss

"" this is a for-profit company " I totally agree but for AVII this is a do or die si…"

arnold replied Sep 18, 2011 to Exon Skipping Confusion

 23 Sep 18, 2011
Reply by Anup Kalra

""5 years for commercial launch of exon 51 skipping"    Coming from the mouth of GSK…"

arnold replied Sep 18, 2011 to Exon Skipping Confusion

 23 Sep 18, 2011
Reply by Anup Kalra

"http://pharmexec.findpharma.com/pharmexec/Noteworthy/Podcast-Interview-Chris-Garabed…"

arnold replied Jun 15, 2011 to AVI Eteplirsen Trial

 1 Jun 15, 2011
Reply by arnold

"Int J Toxicol. 2011 May 3. [Epub ahead of print] Chemical and Mechanistic Toxicology…"

arnold replied May 5, 2011 to Daily pill for Duchenne muscular dystrophy

 1 May 5, 2011
Reply by arnold

"Tomorrow AVI has a webcast and I expect to hear more from the CEO about the Duchenne…"

arnold replied Apr 14, 2011 to AVI BioPharma Receives Approval of Nonproprietary Name Eteplirsen for Lead Duchenne Muscular Dystrophy Therapeutic Candidate, AVI-4658

 10 Apr 18, 2011
Reply by RAKTIM SINGH

"Raktim,   avi is not sitting on a lot of cash, although they just had a stock offeri…"

arnold replied Apr 13, 2011 to AVI BioPharma Receives Approval of Nonproprietary Name Eteplirsen for Lead Duchenne Muscular Dystrophy Therapeutic Candidate, AVI-4658

 10 Apr 18, 2011
Reply by RAKTIM SINGH

"http://finance.yahoo.com/news/AVI-BioPharma-to-Present-Data-iw-750726757.html?x=0&am…"

arnold replied Apr 12, 2011 to AVI BioPharma Receives Approval of Nonproprietary Name Eteplirsen for Lead Duchenne Muscular Dystrophy Therapeutic Candidate, AVI-4658

 10 Apr 18, 2011
Reply by RAKTIM SINGH

"http://investorrelations.avibio.com/phoenix.zhtml?c=64231&p=irol-irhome"

arnold replied Mar 11, 2011 to GSK trial of exon 51 skipping on Ambulatory Boys

 60 Aug 8, 2011
Reply by Wyatt's Mommy, Melissa

RSS

Need help using this community site? Visit Ning's Help Page.

Members

Events

Terms of Service

© 2021   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service